ERASCA, INC.

Profile

Company Names

ERASCA, INC.

Addresses

10835 ROAD TO THE CURE, STE. 140, SAN DIEGO, CA 92121

Phone Numbers

(858) 465-6511

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2018

State Incorporated:

DELAWARE

Total Amount Raised:

$183,683,292.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2020-04-15 
$125,405,005.00 
$374,536,960.00 
$249,131,955.00 
Equity 
1
2018-10-30 
$58,278,287.00 
$70,000,000.00 
$11,721,713.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JAMES 
A. 
BRISTOL, PH.D. 
DIRECTOR
DECIPHERA PHARMACEUTICALS, LLC   |  ERASCA, INC.
ALEXANDER 
W. 
CASDIN 
DIRECTOR
RENEO CAPITAL LP   |  RENEO CAPITAL SPV I LP   |  RENEO CAPITAL SPV II LP   |  RENEO CAPITAL SPV III LP   |  ERASCA, INC.   |  RENEO CAPITAL SPV IV LP   |  RENEO CAPITAL SPV V LP
VALERIE 
 
HARDING-START 
DIRECTOR
ERASCA, INC.
JONATHAN 
 
LIM, M.D. 
EXECUTIVE OFFICER, DIRECTOR
BONTI, INC.   |  ERASCA, INC.   |  BOUNDLESS BIO, INC.
JONATHAN 
E. 
LIM, M.D. 
EXECUTIVE OFFICER, DIRECTOR
IGNYTA, INC.   |  ERASCA, INC.   |  BOUNDLESS BIO, INC.
PRATIK 
S. 
MULTANI, M.D. 
DIRECTOR
IGNYTA, INC.   |  ERASCA, INC.
GARY 
 
YEUNG, CFA 
EXECUTIVE OFFICER
ERASCA, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2020-04-30
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-04-15 
2019-03-11
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-10-30 
2019-01-15
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-10-30 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#